Company intelligence / Profile preview

Galytx

Liverpool, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

Galytx is advancing a portfolio of first-in-class, non-carbohydrate small molecule galectin-3 inhibitors, including a repurposed clinical-stage oral drug and several preclinical assets for injectable use. Their lead clinical asset is repurposed with a strong safety record, currently fast-tracked for cancer and heart failure, while preclinical programs target acute use and additional indications like atopic dermatitis.

Therapeutic areas: CardiovascularImmunologyOtherDermatologyOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Quodria Ltd (atopic dermatitis, Q001)University of LiverpoolEPSRC Hub for Long-Acting Therapeutics

Beyond the preview

Go deeper on Galytx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Galytx.

Explore the full profile